Overview

Study to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia

Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of ACE-536 in patients with beta-thalassemia.
Phase:
Phase 2
Details
Lead Sponsor:
Acceleron Pharma Inc.
Acceleron Pharma, Inc.
Treatments:
Luspatercept